TrialCancer chemotherapy and pharmacology2009

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

Alba A Brandes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.